Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting
Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…Abstract Number: 2725 • 2017 ACR/ARHP Annual Meeting
Understanding Vasculitis Patients’ Ability to Work with Numbers
Background/Purpose: In the case of a complex disease like vasculitis, the patient is often tasked with understanding complicated care plans and managing myriad medications. Without…Abstract Number: 2726 • 2017 ACR/ARHP Annual Meeting
Differentiating Features of Primary Angiitis of Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Evaluation
Background/Purpose: Primary angiitis of central nervous system (PACNS) is an isolated vasculitis affecting small-sized cerebral blood vessels. One of the major mimickers of PACNS is…Abstract Number: 2727 • 2017 ACR/ARHP Annual Meeting
Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study
Background/Purpose: IgA Vasculitis is a leukocytoclastic vasculitis involving small vessels with depositions of immune complexes containing IgA. IgA Vasculitis is a predominantly pediatric vasculitis. There…Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…Abstract Number: 2730 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Treatment of Central Nervous System Vasculitis Associated with Acute Posterior Multifocal Placoid Pigment Epitheliopathy
Background/Purpose: Acute posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) is a rare inflammatory eye disease and some appear to develop central nervous system vasculitis (CNSV). This…Abstract Number: 2731 • 2017 ACR/ARHP Annual Meeting
The Utility of Unbiased Metagenomic Next Generation Sequencing in the Management of Patients with CNS Vasculitis
Background/Purpose: In the clinical approach to CNS vasculitis, exclusion of infection is of major concern as some microbes can cause vasculitis, and infections can complicate…Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…Abstract Number: 2733 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement
Background/Purpose: The international Chapel Hill Consensus Conference (CHCC) categorized Behçet’s disease (BD) as variable vessel vasculitis, which was defined as vasculitis that can affect vessels…Abstract Number: 2734 • 2017 ACR/ARHP Annual Meeting
A Comparison of Current Practice to New Vasculitis Treatment Guidelines
Background/Purpose: Appropriate treatment for Anti-Neutrophilic Cytoplasm Antibodies (ANCA) Associated Vasculitis (AAV) requires induction and maintenance of remission, while balancing side effects from treatment. The CanVasc…Abstract Number: 2735 • 2017 ACR/ARHP Annual Meeting
Is There an Association between Adult IgA Vasculitis and Cancer?
Background/Purpose: An increased incidence rate of cancer has been reported in adult patients with IgA vasculitis (IgAV). These conclusions are mostly based on observations in…Abstract Number: 2736 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival in Systemic Necrotizing Vasculitides
Background/Purpose: The aim of the study was to describe the evolution of mortality over recent decades in systemic necrotizing vasculitides, including polyarteritis nodosa (PAN), granulomatosis…
ACR Meeting Abstracts